(S)-tert-butyl 1-(4-methoxybenzylamino)-3-methyl-1-oxobutan-2-ylcarbamate | 132393-14-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-tert-butyl 1-(4-methoxybenzylamino)-3-methyl-1-oxobutan-2-ylcarbamate
• 英文别名: tert-butyl N-[(2S)-1-[(4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]carbamate
• CAS: 132393-14-7
• 化学式: C₁₈H₂₈N₂O₄
• 分子量: 336.431
• InChiKey: VOWGOKKVHOTXJT-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 1-(4-methoxybenzylamino)-3-methyl-1-oxobutan-2-ylcarbamate 在 劳森试剂 作用下， 以 四氢呋喃 为溶剂， 以265 mg的产率得到C₁₈H₂₈N₂O₃S
  参考文献：
  名称：

  Fine-tuning catalytic activity and selectivity—[Rh(amino acid thioamide)] complexes for efficient ketone reduction

  摘要：

  Amino acid-derived thioamides are prepared and evaluated as ligands in the rhodium-catalyzed asymmetric transfer hydrogenation of ketones in 2-propanol. It is found that increasing the steric bulk at the C-terminus of the ligand had a positive impact on both activity and selectivity in the reduction reaction. In order to find the optimum catalyst, a study is performed on a series of thioamide ligands having substituents of varying size. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.08.116
• 作为产物：
  描述：

  N-Boc-L-缬氨酸 、 4-甲氧基苄胺 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 48.5h， 以70%的产率得到(S)-tert-butyl 1-(4-methoxybenzylamino)-3-methyl-1-oxobutan-2-ylcarbamate
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
  [FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE MTOR

  摘要：

  公式I的化合物：以及其中R1、R2、R2a、R3、n、X和环B具有说明书中给出的含义的盐，是mTOR的抑制剂，可用于治疗对mTOR抑制敏感的疾病，如癌症。

  公开号：

  WO2011029027A1

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE MTOR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011029027A1

  公开（公告）日：2011-03-10

  Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.

  公式I的化合物：以及其中R1、R2、R2a、R3、n、X和环B具有说明书中给出的含义的盐，是mTOR的抑制剂，可用于治疗对mTOR抑制敏感的疾病，如癌症。
• SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
  申请人：Andrews Steven W.

  公开号：US20120178715A1

  公开（公告）日：2012-07-12

  Compounds of Formula I: and salts thereof in which R 1 , R 2 , R 2a , R 3 , n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.

  式I的化合物及其盐，其中R1、R2、R2a、R3、n、X和环B具有规范中所给出的含义，是mTOR的抑制剂，可用于治疗对mTOR抑制敏感的疾病，如癌症。
• Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
  申请人：Andrews Steven W.

  公开号：US08865726B2

  公开（公告）日：2014-10-21

  Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.

  式I的化合物及其盐，其中R1、R2、R2a、R3、n、X和环B的含义如规范中所述，是mTOR的抑制剂，可用于治疗对mTOR抑制敏感的疾病，如癌症。
• US8865726B2
  申请人：——

  公开号：US8865726B2

  公开（公告）日：2014-10-21
• Fine-tuning catalytic activity and selectivity—[Rh(amino acid thioamide)] complexes for efficient ketone reduction
  作者：Katrin Ahlford、Madeleine Livendahl、Hans Adolfsson

  DOI：10.1016/j.tetlet.2009.08.116

  日期：2009.11

  Amino acid-derived thioamides are prepared and evaluated as ligands in the rhodium-catalyzed asymmetric transfer hydrogenation of ketones in 2-propanol. It is found that increasing the steric bulk at the C-terminus of the ligand had a positive impact on both activity and selectivity in the reduction reaction. In order to find the optimum catalyst, a study is performed on a series of thioamide ligands having substituents of varying size. (C) 2009 Elsevier Ltd. All rights reserved.